Head of Startup Lisboa explains Why the City is a Driving Startup Hub!

December 7, 2023

Miguel Fontes, Executive Director of Startup Lisboa, talks to us about their ideas, helping people fulfil their dreams, importance in the ecosystem, partnerships, experiences, things they have accomplished, sharing in business, competition, involving females in business, future of Startup Lisboa, sustainablity in the company, flexibility, reasons why companies are moving to Lisbon, lessons learnt over the years, the future and much more

https://youtu.be/zdknOQsGrjg?si=YiJIC6b2gZyPitIm

Interview by Miguel Salvado.

Via News Video

Video content and multimedia coverage from Via News, bringing you visual insights into markets, business, and finance.

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones

October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,378 source documents archived

Query this data → isubstrate.com

Head of Startup Lisboa explains Why the City is a Driving Startup Hub!

Categories

Tags